<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-3 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-3</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-3</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>cohort_description</strong></td>
                        <td>str</td>
                        <td>Description of the studied cohort relevant to driver-negative LUAD (e.g., TCGA LUAD, clinical sequencing cohort, never-smoker enriched cohort), including inclusion/exclusion criteria if stated.</td>
                    </tr>
                    <tr>
                        <td><strong>sample_size_total</strong></td>
                        <td>int</td>
                        <td>Total number of lung adenocarcinoma tumors/samples analyzed (integer). Null if not stated.</td>
                    </tr>
                    <tr>
                        <td><strong>definition_of_driver_negative</strong></td>
                        <td>str</td>
                        <td>How the paper defines 'driver-negative/unknown driver/pan-negative' (e.g., negative for EGFR/KRAS/ALK/ROS1/BRAF and other common RTK/RAS/RAF alterations; negative on a specific NGS panel; MAPK-pathway negative).</td>
                    </tr>
                    <tr>
                        <td><strong>driver_negative_fraction</strong></td>
                        <td>str</td>
                        <td>Reported fraction/percentage of tumors that are driver-negative in that cohort (include numerator/denominator if provided, e.g., '120/400 (30%)').</td>
                    </tr>
                    <tr>
                        <td><strong>assay_and_platforms</strong></td>
                        <td>str</td>
                        <td>Genomic/omic assays used to search for drivers (e.g., targeted DNA panel, WES, WGS, RNA-seq for fusions, long-read sequencing, methylation arrays, proteogenomics) and key platform details if provided.</td>
                    </tr>
                    <tr>
                        <td><strong>candidate_driver_event</strong></td>
                        <td>str</td>
                        <td>Specific candidate driver alteration/mechanism proposed for driver-negative LUAD (e.g., 'NRG1 fusion', 'MET exon 14 skipping', 'ERBB2 amplification', 'RET fusion', 'EGFR kinase domain duplication', 'ALK IGR fusion', 'KRAS amplification', 'MAPK pathway activation via X', 'MYC amplification', 'TERT promoter mutation', 'STK11/KEAP1-driven metabolic state', 'epigenetic silencing of Y', etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>event_class</strong></td>
                        <td>str</td>
                        <td>Class of alteration: 'SNV/indel', 'copy-number amplification', 'copy-number deletion', 'structural variant/rearrangement', 'gene fusion', 'splice alteration', 'noncoding/regulatory mutation', 'viral insertion', 'epigenetic alteration', 'expression outlier', 'protein activation', or 'microenvironmental/lineage state mechanism'.</td>
                    </tr>
                    <tr>
                        <td><strong>genes_and_pathways_implicated</strong></td>
                        <td>str</td>
                        <td>Key genes and pathways implicated by the event (e.g., RTK/MAPK, PI3K/AKT/mTOR, WNT, Hippo/YAP, NRF2/KEAP1 oxidative stress, cell cycle, telomere maintenance), including whether it is RTK/RAS/RAF-related or an alternative pathway.</td>
                    </tr>
                    <tr>
                        <td><strong>frequency_in_driver_negative_subset</strong></td>
                        <td>str</td>
                        <td>How often this event occurs among driver-negative tumors (e.g., '10% of driver-negative cases', '5/60'), including denominators when possible.</td>
                    </tr>
                    <tr>
                        <td><strong>frequency_in_overall_luad</strong></td>
                        <td>str</td>
                        <td>How often the event occurs in the overall LUAD cohort/population in that paper (e.g., '2% overall'), if stated.</td>
                    </tr>
                    <tr>
                        <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                        <td>str</td>
                        <td>Any reported mutual exclusivity with known drivers (EGFR, KRAS, ALK, ROS1, BRAF, MET, RET, ERBB2, NTRK, etc.) or notable co-occurrence patterns (e.g., with TP53, STK11, KEAP1).</td>
                    </tr>
                    <tr>
                        <td><strong>evidence_type_for_driver_status</strong></td>
                        <td>str</td>
                        <td>Evidence supporting that the event is a driver: statistical recurrence, hotspot pattern, known oncogene mechanism, mutual exclusivity, pathway activation signatures, clonal dominance/VAF, focal amplification, oncogenic fusion structure, etc.</td>
                    </tr>
                    <tr>
                        <td><strong>functional_validation</strong></td>
                        <td>str</td>
                        <td>Any functional experiments supporting driver role (e.g., cell line/organoid dependency, transformation assays, CRISPR knock-in/out, xenograft response). Include model system names if provided.</td>
                    </tr>
                    <tr>
                        <td><strong>therapeutic_implications_and_response</strong></td>
                        <td>str</td>
                        <td>Any targeted therapy suggested or tested for the event and outcomes (e.g., drug names, sensitivity/resistance, clinical responses, trial references). Include response metrics if reported.</td>
                    </tr>
                    <tr>
                        <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                        <td>str</td>
                        <td>Reported expression/proteomic/phosphoproteomic/methylation signatures in driver-negative tumors (e.g., MAPK activation, immune-hot/cold, neuroendocrine features, EMT), and how they relate to proposed drivers.</td>
                    </tr>
                    <tr>
                        <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                        <td>str</td>
                        <td>Any reported TMB values or mutational signatures (e.g., smoking signature, APOBEC) specifically discussed for driver-negative tumors or for specific candidate driver groups.</td>
                    </tr>
                    <tr>
                        <td><strong>histologic_or_clinical_associations</strong></td>
                        <td>str</td>
                        <td>Associations with histology, stage, smoking status, sex, ethnicity, age, or prognosis specific to driver-negative tumors or specific candidate drivers.</td>
                    </tr>
                    <tr>
                        <td><strong>alternative_explanations_or_limitations</strong></td>
                        <td>str</td>
                        <td>Counterpoints/limitations discussed: assay blind spots (e.g., SVs missed by WES/panels), low tumor purity, subclonality, undetected fusions, technical artifacts, passenger vs driver ambiguity, or need for WGS/RNA-seq.</td>
                    </tr>
                    <tr>
                        <td><strong>proposed_mechanistic_model</strong></td>
                        <td>str</td>
                        <td>Concise statement of the paperâ€™s mechanistic explanation for how the alteration drives tumorigenesis in these LUADs (e.g., ligand-dependent signaling, enhancer hijacking, kinase activation, transcriptional reprogramming).</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>